Nivolumab vs Tofacitinib
Nivolumab vs Tofacitinib: Overview
This comparison examines the pharmacological differences between Nivolumab and Tofacitinib.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Tofacitinib: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.
Pharmacokinetics
Half-life: Nivolumab β 27 days; Tofacitinib β 3.2 hours.
Chemical Properties
Molecular Formula: Tofacitinib β C16H20N6O.
Molecular Weight: Tofacitinib β 312.3700 g/mol.
Type: Nivolumab β Antibody; Tofacitinib β Small molecule.